Vaccination Strategy May Hold Key to Ridding HIV Infection From Immune System

Newswise — Using human immune system cells in the lab, AIDS experts at Johns Hopkins have figured out a way to kill off latent forms of HIV that hide in infected T cells long after antiretroviral therapy has successfully stalled viral replication to undetectable levels in blood tests. In a report to be published in the journal Immunity online March 8, the Johns Hopkins team describes a vaccination strategy that boosts other immune system T cells and prepares them to attack HIV, before readying the virus for eradication by reactivating it. HIV has long been known to persist in a dormant, inactive state inside immune system T cells even long after potent drugs have stopped the virus from making copies of itself to infect other cells. But once treatment is stopped or interrupted, the latent virus quickly reactivates, HIV disease progresses, and researchers say it has proven all but impossible to wipe out these pockets of infection. Johns Hopkins senior study investigator and infectious disease specialist Robert Siliciano, M.D., Ph.D., who in 1995 first showed that reservoirs of dormant virus survived, says the resulting need for lifelong drug treatment has raised concerns about the adverse effects of decades of therapy, the growing risk of drug resistance, and the rising cost of care. Siliciano and other AIDS scientists say the best hope for ultimately curing the disease is to force latent viruses to “turn back on,” making them “visible” to the immune system’s so-called cytolytic “killer” T cells and then, with the likely aid of drugs, eliminate the infected cells from the body. In his new study, Siliciano showed that infected T cells survived after latent virus was reactivated, and were only killed off when other immune system T cells were primed before reactivation. “Our study results strongly suggest that a vaccination to boost the immune response immediately prior to reactivating latent virus may be essential for totally eradicating HIV infection,” says Siliciano, a professor at the Johns Hopkins University School of Medicine and a Howard Hughes Medical Institute investigator. In their journal report, Siliciano and his colleagues describe their vaccination strategy and how short pieces of HIV proteins were introduced to stimulate the anti-HIV T-cell response just before reactivation of the latent virus. The incomplete viral proteins and subsequent immune system vaccination led to production of enough cytolytic T cells to attack and kill the latently infected cells. Siliciano and his team next plans to test different methods for boosting the immune response before latent virus reactivation and compare their effectiveness in clearing all HIV- infected cells. Currently, there are more than 34 million people in the world living with HIV, including an estimated 1,178,000 in the United States and 23,000 in the state of Maryland. For additional information, go to:http://www.hopkinsmedicine.org/pharmacology_molecular_sciences/faculty/bios/siliciano.htmlhttp://www.hhmi.org/research/investigators/siliciano_bio.htmlhttp://www.cell.com/immunity/current http://stm.sciencemag.org/content/3/91/91ra63.full.pdf